[go: up one dir, main page]

WO2003064446A3 - Plasma protein-binding peptides from bacterial curli - Google Patents

Plasma protein-binding peptides from bacterial curli Download PDF

Info

Publication number
WO2003064446A3
WO2003064446A3 PCT/EP2003/000943 EP0300943W WO03064446A3 WO 2003064446 A3 WO2003064446 A3 WO 2003064446A3 EP 0300943 W EP0300943 W EP 0300943W WO 03064446 A3 WO03064446 A3 WO 03064446A3
Authority
WO
WIPO (PCT)
Prior art keywords
seq
plasma protein
acid sequence
amino acid
binding peptides
Prior art date
Application number
PCT/EP2003/000943
Other languages
French (fr)
Other versions
WO2003064446A2 (en
Inventor
Lars Bjoerck
Arne Olsen
Mats Wikstroem
Heiko Herwald
Original Assignee
Hansa Medical Res Aktiebolag
Lars Bjoerck
Arne Olsen
Mats Wikstroem
Heiko Herwald
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Medical Res Aktiebolag, Lars Bjoerck, Arne Olsen, Mats Wikstroem, Heiko Herwald filed Critical Hansa Medical Res Aktiebolag
Priority to AU2003239324A priority Critical patent/AU2003239324A1/en
Publication of WO2003064446A2 publication Critical patent/WO2003064446A2/en
Publication of WO2003064446A3 publication Critical patent/WO2003064446A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

An isolated peptide capable of binding a mammalian plasma protein or of generating an immune response in a mammal, the peptide comprising: (a) the amino acid sequence of SEQ ID NO: 1 (NNS24), SEQ ID NO:9 (KQF22) or SEQ ID NO: 10(VDQ26); (b) an amino acid sequence having at least 70% homology to the amino acid sequence of SEQ ID NO:1, 9 or 10; or (c) a fragment of (a) or (b) of at least 6 amino acids in length. The peptide can be used in a method for identifying an antibacterial agent, in a vaccine or in the treatment of a bacterial infection in a human or animal.
PCT/EP2003/000943 2002-01-31 2003-01-30 Plasma protein-binding peptides from bacterial curli WO2003064446A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003239324A AU2003239324A1 (en) 2002-01-31 2003-01-30 Plasma protein-binding peptides from bacterial curli

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0202275.4 2002-01-31
GBGB0202275.4A GB0202275D0 (en) 2002-01-31 2002-01-31 Peptide

Publications (2)

Publication Number Publication Date
WO2003064446A2 WO2003064446A2 (en) 2003-08-07
WO2003064446A3 true WO2003064446A3 (en) 2004-04-01

Family

ID=9930150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/000943 WO2003064446A2 (en) 2002-01-31 2003-01-30 Plasma protein-binding peptides from bacterial curli

Country Status (3)

Country Link
AU (1) AU2003239324A1 (en)
GB (1) GB0202275D0 (en)
WO (1) WO2003064446A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1380290A1 (en) 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
EP1704867A1 (en) * 2005-03-18 2006-09-27 Crossbeta Biosciences B.V. Cross-beta structures on microbial organisms
AU2006267176A1 (en) 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010330A1 (en) * 1992-11-03 1994-05-11 Rea, Teresa, Stanek Fibronectin binding protein as well as its preparation
US6030805A (en) * 1989-05-04 2000-02-29 Normark; Staffan Fibronectin binding protein as well as its preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030805A (en) * 1989-05-04 2000-02-29 Normark; Staffan Fibronectin binding protein as well as its preparation
WO1994010330A1 (en) * 1992-11-03 1994-05-11 Rea, Teresa, Stanek Fibronectin binding protein as well as its preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIAN Z ET AL: "Expression of and cytokine activation by Escherichia coli curli fibers in human sepsis.", THE JOURNAL OF INFECTIOUS DISEASES. UNITED STATES FEB 2000, vol. 181, no. 2, February 2000 (2000-02-01), pages 602 - 612, XP002250170, ISSN: 0022-1899 *
OLSÉN ARNE ET AL: "Identification of two protein-binding and functional regions of curli, a surface organelle and virulence determinant of Escherichia coli.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 13 SEP 2002, vol. 277, no. 37, 13 September 2002 (2002-09-13), pages 34568 - 34572, XP002250171, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU2003239324A1 (en) 2003-09-02
WO2003064446A2 (en) 2003-08-07
GB0202275D0 (en) 2002-03-20

Similar Documents

Publication Publication Date Title
DE60035419D1 (en) ANTIGENIC PEPTIDES FROM NEISSERIA
NZ551802A (en) A hyperimmune serum-reactive antigen consisting of a polypeptide comprising an amino acid sequence in SEQ ID NO:422 and antigenic fragments thereof
WO2006131749A3 (en) Scaffold
SG144692A1 (en) Antigenic proteins of shrimp white spot syndrome virus and uses thereof
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
EP4276463A3 (en) Peptides
TW200716166A (en) Lawsonia intracellularis immunological proteins
ATE408685T1 (en) ANTIMICROBIAL PEPTIDES DERIVED FROM UBIQUICIDINE
NZ592340A (en) A method for making a virus vaccine compising Replikin peptides
NZ335633A (en) Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
FR2828405B1 (en) ANTI-CORONAVIRUS VACCINE
ATE357526T1 (en) MODIFIED HCV PEPTIDE VACCINES
WO2003064446A3 (en) Plasma protein-binding peptides from bacterial curli
DE60313437D1 (en) MHC CLASS I PEPTIDEPITOPES OF HUMAN TUMOR ASSOCIATED ANTIGEN 5T4
DE60332425D1 (en) 5T4-ANTIGEN-PEPTIDEPITOPES OF MHC CLASS II
EE200000478A (en) Peptide, gene encoding it, diagnostic reagent and diagnostic kit, for use in the treatment of rickettsia
NZ515330A (en) Lawsonia derived gene and related OmpH polypeptides, peptides and proteins and their uses
EP1557466A4 (en) Tumor antigen protein and utilization thereof
AU1540795A (en) Diagnosis and treatment of infections due to streptococci and enterococci
EP2143730A3 (en) Modified peptides and their use for the treatment of autoimmune diseases
WO1998040497A3 (en) An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
ATE411812T1 (en) PEPTIDES FOR TREATING HERPES VIRUS INFECTIONS
AU6393990A (en) Hiv related peptides
AU2001239262A1 (en) Haemophilus influenza outer membrane protein and use thereof in vaccination
NZ512308A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP